Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

active_not_recruiting117%
unknown117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
unknown

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

NCT06743776
active_not_recruitingphase_2

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898
completedphase_1

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

NCT03782415
completedphase_2

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
completedphase_1

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06743776

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Unknown
NCT04057898Phase 2

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Active Not Recruiting
NCT03782415Phase 1

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Completed
NCT02238626Phase 2

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT04054206Phase 1

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

Completed
NCT03533387Phase 1

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6